Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NRG Oncology
Centre Oscar Lambret
University of California, San Diego
Dokuz Eylul University
University of Michigan Rogel Cancer Center
University Health Network, Toronto
Radiation Therapy Oncology Group
University Health Network, Toronto
University of Michigan Rogel Cancer Center
Rutgers, The State University of New Jersey
Radiation Therapy Oncology Group
University Health Network, Toronto
Eli Lilly and Company
University College Cork
University of Colorado, Denver
Radboud University Medical Center
Bayer
Aragon Pharmaceuticals, Inc.
Janssen Biotech, Inc.
Hospices Civils de Lyon
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Cedars-Sinai Medical Center
Weill Medical College of Cornell University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Curium US LLC
Institute of Oncology Ljubljana
Ankara University
Leiden University Medical Center
University of Utah
Janssen Research & Development, LLC
University of Washington
Incheon St.Mary's Hospital
Memorial Sloan Kettering Cancer Center
Institut Cancerologie de l'Ouest
Mayo Clinic
Centre Paul Strauss
University Health Network, Toronto
Pfizer
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Thomas Jefferson University
Montefiore Medical Center
University of Illinois at Chicago
University of California, San Diego
University of Michigan Rogel Cancer Center
University of Kansas Medical Center
Tri-Service General Hospital
Medical University of Gdansk
Philogen S.p.A.